Robert Stefanovich Sells 38,700 Shares of CryoPort (NASDAQ:CYRX) Stock

CryoPort, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 38,700 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $7.76, for a total value of $300,312.00. Following the transaction, the chief financial officer owned 255,701 shares in the company, valued at $1,984,239.76. This trade represents a 13.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 16th, Robert Stefanovich sold 2,743 shares of CryoPort stock. The shares were sold at an average price of $8.00, for a total transaction of $21,944.00.

CryoPort Stock Performance

Shares of NASDAQ CYRX opened at $8.36 on Wednesday. The firm has a fifty day moving average of $9.19 and a 200 day moving average of $9.36. The firm has a market cap of $416.83 million, a PE ratio of 6.33 and a beta of 1.69. CryoPort, Inc. has a one year low of $4.63 and a one year high of $11.45.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The company had revenue of $45.45 million for the quarter, compared to analysts’ expectations of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. On average, equities analysts predict that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On CryoPort

A number of institutional investors and hedge funds have recently bought and sold shares of CYRX. Corient Private Wealth LLC acquired a new stake in CryoPort in the 4th quarter valued at about $113,000. Invesco Ltd. boosted its holdings in shares of CryoPort by 19.3% during the 4th quarter. Invesco Ltd. now owns 96,541 shares of the company’s stock worth $927,000 after purchasing an additional 15,607 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of CryoPort in the fourth quarter valued at approximately $424,000. Tudor Investment Corp ET AL grew its position in shares of CryoPort by 3.3% in the fourth quarter. Tudor Investment Corp ET AL now owns 300,414 shares of the company’s stock valued at $2,884,000 after purchasing an additional 9,690 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in shares of CryoPort in the fourth quarter valued at approximately $97,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Analyst upgrade/target increase: Needham raised its target to $13 and reiterated a “buy” view, which supports upside expectations and may be helping the stock’s strength. MarketBeat CYRX Analyst Coverage
• Neutral Sentiment: Mixed Q4 results remain in the backdrop — revenue beat consensus but EPS missed modestly; investors may be parsing near-term profitability versus top-line growth. MarketBeat CYRX Earnings Summary
• Neutral Sentiment: Institutional activity: several small/new stakes were reported (various funds adding modest positions); institutional ownership remains high (~93%), which can reduce float volatility but also concentrate moves. MarketBeat CYRX Institutional Ownership
• Negative Sentiment: Insider selling — CEO Jerrell Shelton sold 7,918 shares at an average $8.00 on Mar 16 (ownership decreased ~0.75%), a signal some investors view as negative. CEO SEC Filing
• Negative Sentiment: Significant CFO selling — Robert Stefanovich disclosed a larger sale on Mar 12 of 38,700 shares (~13.15% of his prior holding) and additional sales on Mar 16 (2,743 shares). Large insider liquidation by a senior finance officer can weigh on sentiment. CFO SEC Filing
• Negative Sentiment: Additional insider sales: Mark W. Sawicki sold 3,235 shares and Edward J. Zecchini sold 2,014 shares on Mar 16 — cumulatively these insider dispositions add to negative optics even if dollar amounts are modest. Insider SEC Filings

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CYRX. Weiss Ratings reissued a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Needham & Company LLC boosted their price target on CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Wall Street Zen downgraded CryoPort from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.94.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.